Increase in antiepileptic efficacy during prolonged treatment with valproic acid: Role of inhibition of histone deacetylases?

Epilepsy Research

Volumn 81, Issue 2-3, 2008, Pages 107-113

  Hoffmann, Katrin ^a   Czapp, Marion ^a   Löscher, Wolfgang ^a  

^a CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Epilepsy; GABA; Mice; Pentylenetetrazole; Valproate

Indexed keywords

HISTONE DEACETYLASE; PENTETRAZOLE; TRICHOSTATIN A; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN; CLONIC SEIZURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HYPOTHESIS; MOUSE; MYOCLONUS SEIZURE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TONIC SEIZURE;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY, GENERALIZED; FEMALE; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MICE; PENTYLENETETRAZOLE; PROTEIN SYNTHESIS INHIBITORS; TIME FACTORS; VALPROIC ACID;

EID: 53249147679     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2008.04.019     Document Type: Article

References (43)

1. Altrup U., Gerlach G., Reith H., Said M.N., and Speckmann E.-J. Effects of valproate in a model nervous system buccal ganglia of Helix pomatia: I. Antiepileptic actions. Epilepsia 33 (1992) 743-752
2. Avila A.M., Burnett B.G., Taye A.A., Gabanella F., Knight M.A., Hartenstein P., Cizman Z., Di Prospero N.A., Pellizzoni L., Fischbeck K.H., and Sumner C.J. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117 (2007) 659-671
3. Beydoun A.A., Farrell K., and Nasreddine W.M. Valproate. In: Engel Jr. J., and Pedley T.A. (Eds). Epilepsy. A comprehensive Textbook (2008), Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia 1673-1682
4. Bialer M., and Yagen B. Valproic acid: second generation. Neurotherapeutics 4 (2007) 130-137
5. Bojic U., Elmazar M.M., Hauck R.S., and Nau H. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem. Res. Toxicol. 9 (1996) 866-870
6. Bourgeois B.F.D. Valproic acid. Clinical efficacy and use in epilepsy. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs. fifth edition (2002), Lippincott Williams & Wilkins, Philadelphia 808-817
7. Brandt C., Gastens A.M., Sun M.Z., Hausknecht M., and Löscher W. Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 51 (2006) 789-804
8. Costa E., Dong E., Grayson D.R., Ruzicka W.B., Simonini M.V., Veldic M., and Guidotti A. Epigenetic targets in GABAergic neurons to treat schizophrenia. Adv. Pharmacol. 54 (2006) 95-117
9. Davis R., Peters D.H., and Mctavish D. Valproic acid-a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47 (1994) 332-372
10. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370 (2003) 737-749
11. Dong E., Agis-Balboa R.C., Simonini M.V., Grayson D.R., Costa E., and Guidotti A. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 12578-12583
12. Eikel D., Lampen A., and Nau H. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem. Res. Toxicol. 19 (2006) 272-278
13. Fisher J.E., Nau H., and Löscher W. Alterations in the renal excretion of valproate and its metabolites after chronic treatment. Epilepsia 32 (1991) 146-150
14. Göttlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo C.F., Nervi C., Pelicci P.G., and Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20 (2001) 6969-6978
15. Göttlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann. Hematol. 83 Suppl. 1 (2004) S91-S92
16. Gurvich N., Tsygankova O.M., Meinkoth J.L., and Klein P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 64 (2004) 1079-1086
17. Huang Y., Doherty J.J., and Dingledine R. Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. J. Neurosci. 22 (2002) 8422-8428
18. Jessberger S., Nakashima K., Clemenson Jr. G.D., Mejia E., Mathews E., Ure K., Ogawa S., Sinton C.M., Gage F.H., and Hsieh J. Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. J. Neurosci. 27 (2007) 5967-5975
19. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., and Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321 (2007) 892-901
20. Korzus E., Rosenfeld M.G., and Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42 (2004) 961-972
21. Kostrouchova M., Kostrouch Z., and Kostrouchova M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol. (Praha) 53 (2007) 37-49
22. Levy R.H., Shen D.D., Abbott F.S., and Hachad H. Valproic acid. Chemistry, biotransformation, and pharmacokinetics. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott Williams & Wilkins, Philadelphia 780-800
23. Löscher W., and Frey H.-H. Effect of convulsant and anticonvulsant agents on level and metabolism of y-aminobutyric acid in mouse brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 296 (1977) 263-269
24. Löscher W., and Nau H. Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice. Arch. Int. Pharmacodyn. Ther. 257 (1982) 20-31
25. Löscher W., Hönack D., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazol seizure models. Epilepsy Res. 8 (1991) 171-189
26. Löscher W., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 8 (1991) 79-94
27. Löscher W., and Hönack D. Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ("controlled release") administration in a model of generalized seizures in rats. Epilepsia 36 (1995) 929-937
28. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58 (1999) 31-59
29. Löscher W. Valproate (1999), Birkhäuser, Basel
30. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16 (2002) 669-694
31. McLaughlin F., and La Thangue N.B. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol. 68 (2004) 1139-1144
32. Menegola E., Di Renzo F., Broccia M.L., and Giavini E. Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Res. C Embryo Today 78 (2006) 345-353
33. Owens M.J., and Nemeroff C.B. Pharmacology of valproate. Psychopharmacol. Bull. 37 Suppl. 2 (2003) 17-24
34. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
35. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10 (2004) 685-692
36. Saha R.N., and Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 13 (2006) 539-550
37. Santini V., Gozzini A., and Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr. Drug Metab. 8 (2007) 383-393
38. Shen D.D. Valproate: absorption, distribution, and excretion. In: Löscher W. (Ed). Valproate (1999), Birkhäuser, Basle 77-90
39. Soghomonian J.J., and Martin D.L. Two isoforms of glutamate decarboxylase: why?. Trends Pharmacol. Sci. 19 (1998) 500-505
40. Tremolizzo L., Carboni G., Ruzicka W.B., Mitchell C.P., Sugaya I., Tueting P., Sharma R., Grayson D.R., Costa E., and Guidotti A. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 17095-17100
41. Walter, D.S., Tulloch, I.F., Salt, T.E., Howe, G.M., 1980. Anti-epileptic Compounds: Future Possibilities. In: Parsonage, M.J., Caldwell, A.D.S. (Eds.), The place of sodium valproate in the treatment of epilepsy. Academic Press, London, pp. 201-206.
42. White H.S. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 44 Suppl. 7 (2003) 2-8
43. Yoshida M., Kijima M., Akita M., and Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265 (1990) 17174-17179